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Introduction
Cyclotides are small (28 to 37 residues) globular microproteins
that posses a unique head-to-tail cyclized backbone that is
stabilized by three disulfide bonds forming a cystine-knot
motif.[1, 2] The cyclic cystine-knot (CCK) molecular scaffold pro-
vides a very rigid molecular platform[3–5] that confers an excep-
tional stability towards physical, chemical, and biological deg-
radation.[1,2] Cyclotides can be considered to be natural combi-
natorial peptide libraries that are structurally constrained by
the cystine-knot scaffold and head-to-tail cyclization, but in
which hypermutation of essentially all residues is permitted—
with the exception of the strictly conserved cysteines that hold
the knot together.[6–8] In addition, naturally occurring cyclotides
have been shown to posses pharmacologically relevant activi-
ties.[1, 9] Cyclotides have also been engineered to target extra-
[10–12] and intracellular[13] molecular targets in animal models.
Some of these novel cyclotides have been shown to be orally
bioavailable[11] and able to efficiently cross cellular mem-
branes.[14–16] Together, these features make the cyclotide scaf-
fold an excellent molecular framework for the design of new
peptide-based therapeutics.[2, 17]
Naturally occurring cyclotides are ribosomally produced in
plants from precursors that comprise one to three do-
mains.[18–21] However, the mechanism of excision of the cyclo-
tide domains and ligation of the free N and C termini to pro-
duce the circular peptides has not yet been completely eluci-
dated, although it has been speculated that asparaginyl endo-
peptidases are involved in the cyclization process.[22–24] Cyclo-
tides can also be produced recombinantly by using standard
microbial expression systems and making use of modified pro-
tein-splicing units,[25–28] thus allowing the production of biolog-
ically generated libraries of these microproteins for the first
time.[26]
The relatively small size of cyclotides also makes it possible
to employ chemical tools to generate synthetic combinatorial
libraries based on this scaffold for the screening and selection
of optimized sequences for a particular biological activity.
Chemical libraries have some advantages over biologically pro-
duced libraries, for example, chemical libraries are not con-
strained to natural amino acids and can include both unnatural
and d-amino acids, in addition to secondary structures not tol-
erated by the ribosome. As unnatural and d-amino acids are
less susceptible to proteases and peptidases than natural l-
amino acids, chemical libraries have the potential to rapidly
identify stable and bioactive peptide sequences. In addition,
chemical libraries allow the incorporation of post-translational
modifications, such as glycosylation and phosphorylation,
which are not accessible in bacterial expression systems.
The chemical synthesis of several naturally occurring and en-
gineered cyclotides has been already accomplished by solid-
phase peptide synthesis (SPPS) using either Boc-[29,30] or Fmoc-
based[10,13,14, 31–33] chemistry. All of them use intramolecular
native chemical ligation (NCL)[34,35] to cyclize the backbone fol-
lowed by oxidative folding to produce the natively folded cy-
clotide. Our group has recently reported that the cyclization
and oxidative folding reactions can be efficiently performed in
a one-pot reaction when carried out in aqueous phosphate
buffer (pH 7.2) in the presence of reduced glutathione
(GSH).[10,13, 14] Under these conditions, folded cyclotides can be
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produced very efficiently in one step from the corre-
sponding linear precursor with minimal purifica-
tion;[10, 13,14] minimizing the number of steps required
to produce cyclotides being key to the production
of large libraries. This approach has also been re-
cently used for the rapid and efficient production of
other disulfide-rich, backbone-cyclized polypeptides,
such as the cyclic defensin RTD-1.[36]
The production of combinatorial peptide-based li-
braries requires the parallel synthesis of many pep-
tides. The “tea-bag” approach was one the first de-
veloped.[37] This approach is well suited for the pro-
duction of medium-sized libraries (3102) for anti-
genic mapping,[38] and to produce amino-acid-scan-
ning[39, 40] and positional-scanning libraries.[41] This
approach, however, has been mostly used to pro-
duce small (10–15 residues) linear peptides, and it
has never been explored for the production of libra-
ries of large, complex, folded polypeptides such as
cyclotides.
In this work, we report the first rapid parallel syn-
thesis of a small library of folded bioactive cyclotides
by using a tea-bag approach in combination with
optimized cyclization/folding protocols that require
minimal purification steps. As a model system, we
used the cyclotide MCo-CVX-5c (Figure 1), a potent
antagonist of the CXCR4 reporter.[10] Using this ap-
proach, we were able to rapidly produce 15 cyclotides based
on MCo-CVX-5c that were tested to rapidly evaluate structur-
al–activity relationships.
Results and Discussion
Library design
We used the cyclotide MCo-CVX-5c as a model to evaluate the
parallel synthesis of cyclotides by the tea-bag approach. This
cyclotide was engineered to inhibit the CXCR4 receptor by
grafting a topologically modified CVX15-based peptide onto
loop six of cyclotide MCoTI-I (Figure 1).[10] This cyclotide has
been shown to be a potent CXCR4 antagonist and an efficient
HIV-1 cell-entry blocker.[10] In order to improve the activity of
this cyclotide, we explored potential mutations located in the
neighboring loops to the loop used for the graft that could
stabilize the interaction between the cyclotide and the recep-
tor. We first built a model of cyclotide MCo-CVX-5c bound to
the CXCR4 receptor (Figure 1A). This was accomplished, as pre-
viously described,[10] by using the solution structure of cyclo-
tide MCoTI-II (PDB ID: 1IB9)[42] and the crystal structure of
CVX15 bound to the CXCR4 receptor (PDB ID: 3OE0)[43] as mo-
lecular templates. According to this model, residue 12 in
loop 2 is in close proximity to the CXCR4 extracellular surface
receptor. Accordingly, to explore the effect of this residue on
the biological activity of MCo-CVX-5c, we made a small library
of cyclotides based on MCo-CVX-5c in which the native Asp
residue in this position was mutated to residues containing dif-
ferent chemical functionalities (Figure 1B). The set of amino
acids that were tested comprised negative (Glu) and positive
(Lys, His) charged, aliphatic (Ala, Ile, Leu) and aromatic (Tyr,
Trp), hydrophilic (Asn, Gln, Ser, Thr), N-alkylated (Pro) and small
(Gly) residues.
Library synthesis
All 15 cyclotides (including the control, MCo-CVX-5c, called
“WT” from here on; Table 1) were chemically synthesized
through Fmoc-based SPPS on a sulfonamide resin[44–46] and a
tea-bag approach. We used the peptide bond between resi-
dues Tyr26 and Cys27 as the cyclization site. This site has been
shown to provide very good yields with different MCoTI-based
cyclotide sequences,[13,14] including the WT.[10] The common C-
terminal sequence (Tyr26–Ser13) for all cyclotides was synthe-
sized on the 0.1 mmol scale on an automated peptide synthe-
sizer. At this point, the resin was divided into 15 equimolar ali-
quots each containing around 4–6 mmol (25 mg; Figure 2).
Each resin was manually coupled in parallel with the corre-
sponding Fmoc-activated amino acid derivative. Once the cou-
plings were complete, each resin was placed in an individual
sealed polypropylene tea-bag of around 3020 mm, properly
tagged for identification, and the synthesis was continued on
the synthesizer in an ABI433A 0.25 mmol scale reaction vessel,
which has a capacity of 42 mL (Figure 2). This reaction vessel
was able to accommodate up to nine such tea-bags. The
number of tea-bags, however, could easily be increased by
using smaller ones. Accordingly, the common N-terminal seg-
ment for the 15 different cyclotides was synthesized in two
steps, the first with nine and the second with six tea-bags.
Figure 1. Design of the amino-acid-scanning library for position 12 in loop 2 of cyclotide
MCo-CVX-5c (WT). A) Structural model of the molecular complex between MCo-CVX-5c
and the CXCR4 receptor, Asp12 is in close proximity to the extracellular surface of
CXCR4. B) Sequence and disulfide connectivities (gray) of MCo-CVX-5c and the ana-
logues. The black line indicates the backbone cyclization between the a-NH2 and the
a-carboxylate groups of residues 1 and 43, respectively. The cyclization site is indicated
with an arrow. Single-letter codes B, X, and p represent 2-naphthylalanine, citruline, and
d-proline, respectively. Molecular graphics were built with Yasara (http://www.yasara.
org).
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Once the synthesis of all the analogues was complete, the cor-
responding peptide sulfonamide-resins were activated in paral-
lel with iodoacetonitrile ; this was followed by cleavage with
ethyl mercaptoacetate and acidolytic deprotection to give the
fully deprotected linear peptide a-thioesters precursors (Fig-
ure 2). The crude peptide mixtures were characterized by HPLC
and ES-MS, and in all the cases the major product was the cor-
responding linear precursor thioester (Figures S1 and S2).
Library cyclization/folding and purification
The peptide thioester precursors were directly cyclized and
folded in parallel in a one-pot reaction in sodium phosphate
buffer (pH 7.2) with 1 mm GSH. Under these conditions WT cy-
clotide has been shown by NMR spectroscopy to cyclize and
adopt a native conformation.[10] The cyclization/folding reac-
tions were followed by HPLC and shown to be complete in
24–96 h. Most of the cyclotides were able to cyclize and fold
with yields similar to that of WT (80%), only cyclotides D12I,
D12L, D12Y, and D12W showed lower yields, with several late-
Table 1. Nomenclature used for all the MCo-CVX-based cyclotide used in
this work. All the cyclotides sequence are based on cyclotide MCo-CVX-
5c.
Aaa12[a] Cyclotide Molecular weight [Da]
name Found Expected average isotopic
Asp WT 5056.70.8 5056.9
Ala D12A 5012.80.3 5012.9
Glu D12E 5070.80.8 5070.9
Gly D12G 4998.60.6 4998.9
His D12H 5078.90.8 5078.9
Lys D12K 5069.80.6 5070.0
Ile D12I 5054.80.6 5054.9
Leu D12L 5054.70.5 5054.9
Asn D12N 5055.90.5 5055.9
Pro D12P 5039.50.6 5038.9
Gln D12Q 5069.90.1 5069.9
Ser D12S 5028.70.4 5028.9
Thr D12T 5043.11.0 5042.9
Trp D12W 5127.91.0 5128.0
Tyr D12Y 5104.51.0 5105.0
[a] Amino acid at position 12 in loop 2 of cyclotide MCo-CVX-5c
(Figure 1).
Figure 2. Synthetic scheme for the parallel production of the amino-acid-scanning library at position 12 of MCo-CVX-5c by using a tea-bag approach.
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eluting by-products that were attributed to partially folded
and/or GSH adducts, as determined by ES-MS analysis (Fig-
ures 3 and S4). The formation of alternative structures with
shuffled SS bonds was not observed for any of the cyclotides
studied in this work. The conditions used in this work for the
oxidative folding, which involve thermodynamic control under
slightly reductive conditions, favor the accumulation of prod-
ucts containing the more stable cyclotide scaffold.[10] Removal
of partially folded and/or GSH–peptide adducts was readily ac-
complished by using activated thiopropyl–Sepharose chroma-
tography. Activated thiopropyl–Sepharose beads contain a reac-
tive disulfide that reacts covalently with molecules containing
free thiol groups, thereby removing any partially folded prod-
uct from the crude reaction (Figure 3A). Accordingly, fully
folded cyclotides are eluted from the column along with 2-
mercaptopyridone, which can be easily removed by dialysis. As
shown in Figure 4, this approach was successfully used to pro-
duce 14 of the 15 cyclotides in high purity (80–90%, as de-
termined by HPLC and ES-MS). For most cell-based assays this
level of purity is usually satisfactory.[10] In addition, we tested
the activity of some of the cyclotides purified by HPLC and
compared them with the activities obtained with the same cy-
clotides purified by just using the activated thiopropyl–Sephar-
ose, and the values were similar.[10]
Only cyclotide, D12W, was obtained with a lower degree of
purity (70%, as determined by HPLC and ES-MS). This was at-
tributed to the higher reactivity of Trp-containing peptides of
the linear peptide precursor. It is also important to note that
this purification approach can be easily used in parallel to
purify a single cyclotide compound, but also, and more impor-
tantly, to purify mixtures of cyclotides, as it relies only on the
ability of the polypeptide/s to adopt a cyclotide fold with no
free thiol groups. Consequently, this approach to remove un-
folded and partially folded compounds is potentially compati-
ble with the production of positional scanning libraries from
the cyclotide scaffold.
Biological activity against the CXCR4 receptor
To evaluate the effect of the different mutations on the biolog-
ical activity of the corresponding cyclotide analogues, we
tested the ability of the CVX15-grafted cyclotides to inhibit
SDF1a-mediated CXCR4 activation by using a CXCR4–b-lacta-
mase U2OS cell-based fluorescence assay (Figure 5). All the cy-
clotides tested were able to inhibit SDF1a-mediated CXCR4 ac-
tivation in a dose-dependent manner, with IC50 values ranging
from 3.50.1 (D12H) to 458 nm (D12Y). The empty scaffold
cyclotide MCoTI-I has already been shown to have no inhibito-
ry activity in this assay,[10] and so was not included in this
study. The small molecule AMD3100[47] was also included as
positive control. As previously described, the activity of the WT
cyclotide was similar to that of AMD3100 in this type of assay,
thus indicating the relatively high potency of this cyclotide. As
expected, the D12E mutation did not lead to a change in activ-
ity. Most of the other mutations tested in this work did not sig-
nificantly change the activity of the resulting cyclotides. Intri-
guingly, replacing the original Asp amino acid by a positively
charged residue had no or very little effect on the biological
activity of the resulting cyclotides. For example, cyclotide D12K
(IC50=92 nm) was only about two times less potent than the
WT cyclotide, and cyclotide D12H (IC50=3.50.5 nm) had prac-
tically the same activity as the WT cyclotide. Cyclotide D20P
(IC50=203 nm) also showed a slight decrease in activity,
being about four times less active than WT); this could be at-
tributed to the conformational restrictions imposed by the Pro
residue. Among the analogues tested in this study, only cyclo-
tides D12Y (IC50=458 nm) and D12W (IC50=304 nm) led
to a significant decrease in biological activity, being both
almost 10 times less active than the WT cyclotide. Together,
these results indicate that position 12 is quite tolerant to mu-
tations, and only the introduction of aromatic residues (Trp
and Tyr) seems to have a significant detrimental effect on the
biological activity of the resulting cyclotides.
Conclusions
In summary, we have shown for the first time that bioactive
folded MCoTI-based cyclotides can be efficiently produced in
Figure 3. Purification of folded cyclotides from the one-pot cyclization–fold-
ing reaction by using activated thiopropyl–Sepharose beads. A) Principle for
the removal of unfolded and/or partially folded cyclotides from the cycliza-
tion–folding reaction by using activated thiopropyl–Sepharose beads. Un-
folded and/or partially folded peptides have free thiol groups that are cap-
tured by and immobilized onto the Sepharose beads. Fully folded cyclotides
do not contain any free thiols and therefore are not captured. The capture
reaction also produces 2-mercaptopyridone, which can easily be removed in
a separate dialysis step. B) Analytical HPLC analysis of the purification of cy-
clotide D12L by using activated thiopropyl–Sepharose beads followed by di-
alysis. The cyclization–folding reaction in this cyclotide analogue produced
some late-eluting by-products that were attributed to partially folded cyclo-
tides and GSH adducts. All of these by-products contain free-thiol groups
and were efficiently captured by the activated Sepharose beads to yield
folded cyclotide with a high level of purity, as determined by HPLC and ES-
MS (Figures S3 and S4). HPLC analysis was performed with a linear gradient
of 0–70% solvent B over 30 min. An asterisk marks the product correspond-
ing to the folded cyclotide as determined by ES-MS analysis.
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parallel by using a tea-bag approach in combination with
highly efficient cyclization-folding protocols. The approach de-
scribed in this work also includes an efficient purification pro-
cedure to rapidly remove unfolded or partially folded cyclo-
tides from the cyclization-folding crude. This procedure can be
easily used in parallel to purify individual compounds, but also,
and more importantly, to purify cyclotide mixtures. These
qualities make it potentially compatible with the synthesis of
positional scanning libraries in order to efficiently screen large
libraries.
These protocols were successfully used to produce a small li-
brary of bioactive cyclotides based on the cyclotide MCo-CVX-
5c (WT), which is a potent CXCR4 antagonist recently devel-
oped in our group.[10] Biological evaluation of this library al-
lowed rapid assessment of the effects of single mutations on
the activity of the corresponding cyclotide analogues. The re-
sults of the mutation of position 12 of loop 2 indicated that
none of the mutations improved on the activity of the WT cy-
clotide, but that this position was quite tolerant of most of the
mutations tested, except for those containing aromatic side
chains. These results open up the possibility of studying other
positions and/or loops within this bioactive cyclotide through
the use of amino-acid- or positional-scanning libraries. In sum-
mary, our results demonstrate for the first time the efficient
parallel synthesis of bioactive folded cyclotides thereby provid-
ing a powerful chemical tool for evaluating structure–activity
relationships in large complex polypeptides in a rapid and effi-
cient fashion.
Figure 5. Biological characterization of all the MCo-CVX-based cyclotides
produced in this work. Competitive inhibition of SDF1a-mediated CXCR4 ac-
tivation by the different cyclotide analogues. The small-molecule CXCR4 an-
tagonist AMD3100 was used as control. The assay was performed in CXCR4-
bla U2OS cells as described in the Experimental Section.
Figure 4. Analytical HPLC analysis of all the
cyclotides used in this work after they had
been purified by activated thiopropyl–Se-
pharose beads and dialysis. HPLC analysis
was performed with a linear gradient of 0–
70% solvent B over 30 min. An asterisk marks
the product corresponding to the folded cy-
clotide as determined by ES-MS analysis.
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Experimental Section
Analytical HPLC was performed on a HP1100 series instrument
with 220 and 280 nm detection by using a Vydac C18 column
(5 mm, 4.6150 mm) at a flow rate of 1 mLmin1. All runs used
linear gradients of 0.1% aqueous trifluoroacetic acid (TFA, sol-
vent A) versus 0.1% TFA, 90% acetonitrile in H2O (solvent B). UV/
Vis spectroscopy was carried out on an Agilent 8453 diode-array
spectrophotometer, and fluorescence analysis was performed on
a Jobin Yvon Flurolog-3 spectroflurometer. Electrospray mass spec-
trometry (ES-MS) analysis was routinely applied to all cyclized pep-
tides. ES-MS experiments were performed on a Applied Biosystems
API 3000 triple quadrupole mass spectrometer.
Preparation of Fmoc-Tyr(tBu)-F: Fmoc-Tyr(tBu)-F was prepared by
using diethylaminosulfur trifluoride (DAST), as previously de-
scribed[14] and quickly used afterwards. Briefly, DAST (160 mL,
1.2 mmol) was added dropwise at 25 8C under a nitrogen current
to a stirred solution of Fmoc-Tyr(tBu)-OH (459.6 mg, 1 mmol) in dry
CH2Cl2 (10 mL) containing dry pyridine (81 mL, 1 mmol). After
20 min, the mixture was washed with ice-cold water (320 mL).
The organic layer was separated and dried over anhydrous MgSO4.
The solvent was removed under reduced pressure to give the cor-
responding Fmoc-amino acyl fluoride as white solid that was im-
mediately used.
Loading of 4-sulfamylbutyryl AM resin with Fmoc-Tyr(tBu)-F:
The first residue was loaded by using Fmoc-Tyr(tBu)-F as previously
described.[10] Briefly, 4-sulfamylbutyryl AM resin (420 mg,
0.33 mmol; Novabiochem) was swollen for 20 min with dry CH2Cl2
and then drained. A solution of Fmoc-Tyr(tBu)-F (461 mg,
1 mmol) in dry CH2Cl2 (2 mL) and di-isopropylethylamine (DIEA;
180 mL, 1 mmol) was added to the drained resin, and the mixture
was allowed to react at 25 8C for 1 h. The resin was washed with
dry CH2Cl2 (55 mL), dried and kept at 20 8C until use.
Chemical synthesis of the cyclotide-based library: All peptides
were synthesized as described in Figure 2 by solid-phase synthesis
on an automatic peptide synthesizer ABI433A (Applied Biosystems)
by using the Fast-Fmoc chemistry with a 2-(1H-benzotriazol-1-yl)-
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU)/DIEA acti-
vation protocol on a 0.1 mmol scale on a Fmoc-Tyr(tBu)-sulfamyl-
butyryl AM resin. Side-chain protection compatible with Fmoc
chemistry was employed, as previously described,[10] for the synthe-
sis of peptide a-thioesters by the Fmoc-protocol, except for the N-
terminal Cys residue, which was introduced as Boc-Cys(Trt)-OH.
Before the coupling of residue 12, the peptide–resin was manually
resuspended in CH2Cl2/DMF (1:1) and split into 15 equal aliquots.
Each peptide–resin aliquot was placed in a separate 1 mL poly-
propylene column (Qiagen). The resins were manually deprotected
with 20% 4-methylpiperidine in DMF (35 min) and then individu-
ally coupled with each of the different 15 Fmoc-Aaa-OH (Figures 1
and 2). Couplings were performed with HBTU and DIEA for 45 min.
The resins were then washed, dried, placed in individual tagged
tea-bags (3020 mm) and sealed. The synthesis was continued in
the peptide synthesizer 0.25 mmol reaction vessel, which can hold
up to nine different tea-bags of the dimensions reported above.
This required two synthetic steps, the first with nine and the
second with six tea-bags in the reaction vessel. Following chain as-
sembly, alkylation, thiolytic cleavage and side-chain deprotection
were performed for individual peptides in 1 mL polypropylene col-
umns, as previously described.[14] Briefly, protected peptide–resin
(10 mg) was first alkylated twice with ICH2CN (17.4 mL,
0.24 mmol; previously filtered through basic alumina) and DIEA
(8.2 mL, 0.046 mmol) in N-methylpyrrolidone (NMP; 0.22 mL) for
24 h. The resin was then washed with NMP (35 mL) and CH2Cl2
(35 mL). The alkylated peptide resin was cleaved from the resin
with HSCH2CH2CO2Et (20 mL, 0.18 mmol) in the presence of a cata-
lytic amount of sodium thiophenolate (NaSPh, 0.3 mg, 2.2 mmol) in
DMF/CH2Cl2 (1:2, v/v, 0.12 mL) for 24 h. The resin was then dried at
reduced pressure. The side-chain-protecting groups were removed
by treating the dried resin with TFA/H2O/tri-isopropylsilane (TIS;
95:3:2, v/v/v, 0.5 mL) for 3–4 h at room temperature. The resin was
filtered, and the linear peptide thioester was precipitated in cold
Et2O. The crude material was dissolved in a minimal amount of
H2O/MeCN (4:1) containing 0.1% TFA and characterized by HPLC
and ES-MS as the desired grafted MCoTI-I linear precursor a-thio-
ester (Figure S1 and S2). Cyclization and folding were accom-
plished by flash dilution of the linear a-thioester TFA crude to
a final concentration of 20–50 mm into freshly degassed reduced
glutathione (GSH, 2 mm), sodium phosphate buffer (0.1m, pH 7.2)
for 96 h.
Purification of folded cyclotides by using activated thiopropyl–
Sepharose beads: Following oxidative folding, the pH of the cycli-
zation-folding crude was raised to 8.0 by slowly adding an aqueous
solution of Na3PO4 (0.2m). After 4 h, the resulting crudes were
treated with pre-swollen activated thiopropyl–Sepharose beads
(20 mL of swollen beads per mL of cyclization-folding crude, Phar-
macia) for 1 h. The beads were then drained and washed with
10% HOAc in water (2200 mL). The combined liquid fractions
were pooled and dialyzed in a slide-A-lyzer mini dialysis (Thermo-
scientific) with a cut-off of 3.5 kDa against HOAc (0.1m, 214 mL).
The dialyzed samples were then analyzed by HPLC and ES-MS for
purity (Figures 4 and S4), lyophilized and stored at 20 8C. Purified
cyclotides were quantified by UV/Vis spectroscopy at 280 nm by
using a molar absorptivity coefficient of 10470m1 cm1 for all the
cyclotides except for D12Y (11810m1 cm1) and D12W
(16020m1 cm1).
Cell-based CXCR4 competitive-binding assays: Briefly, Tango
CXCR4-bla U2OS cells (Life Technologies) were seeded at 11000
cells per well in 384-well tissue culture plate for 24 h in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 1% FBS.
Cells were pre-treated with various concentrations of inhibitors for
30 min prior to the addition of SDF-1a (30 nm), then incubated for
5 h at 37 8C. b-Lactamase substrate LiveBLAzer-FRET B/G Substrate
(Invitrogen) was incubated with treated cells for 2 h at room tem-
perature, and the fluorescence signal was measured by Synergy H1
plate reader (Bio Tek) at 409/460 nm (substrate cleaved) and 409/
530 nm (substrate uncleaved).
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